Alberts CJ, et al. Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: A systematic review. Lancet Gastroenterol Hepatol 2022; 7: 724–735. doi: 10.1016/S2468-1253(22)00050-4
Gupta A, Quigg RJ. Glomerular diseases associated with hepatitis B and C. Adv Chronic Kidney Dis 2015; 22: 343–351. doi: 10.1053/j.ackd.2015.06.003
Kupin WL. Viral-associated GN: Hepatitis B and other viral infections. Clin J Am Soc Nephrol 2017; 12: 1529–1533. doi: 10.2215/CJN.09180816
Liao M-T, et al. Universal hepatitis B vaccination reduces childhood hepatitis B virus-associated membranous nephropathy. Pediatrics 2011; 128:e600–e604 doi: 10.1542/peds.2010-3137
Neurath AR, Strick N. Host specificity of a serum marker for hepatitis B: Evidence that “e antigen” has the properties of an immunoglobulin. Proc Natl Acad Sci USA 1977; 74: 1702–1706. doi: 10.1073/pnas.74.4.1702
Gilbert RD, Wiggelinkhuizen J. The clinical course of hepatitis B virus-associated nephropathy. Pediatr Nephrol 1994; 8: 11–14. doi: 10.1007/BF00868249
Lai KN, et al. Membranous nephropathy related to hepatitis B virus in adults. N Engl J Med 1991; 324: 1457–1463. doi: 10.1056/NEJM199105233242103
Tang S, et al. Lamivudine in hepatitis B-associated membranous nephropathy. Kidney Int 2005; 68: 1750–1758. doi: 10.1111/j.1523-1755.2005.00591.x
Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int 2021; 100:S1–S276. doi: 10.1016/j.kint.2021.05.021
Zheng X-Y, et al. Meta-analysis of combined therapy for adult hepatitis B virus-associated glomerulonephritis. World J Gastroenterol 2012; 18: 821–832. doi: 10.3748/wjg.v18.i8.821
Li H, et al. Efficacy of adefovir dipivoxil combined with a corticosteroid in 38 cases of nephrotic syndrome induced by hepatitis B virus-associated glomerulonephritis. Ren Fail 2014; 36: 1404–1406. doi: 10.3109/0886022X.2014.952745
Pouteil-Noble C, et al. Glomerular disease associated with hepatitis C virus infection in native kidneys. Nephrol Dial Transplant 2000; 15 (Suppl 8):28–33. doi: 10.1093/ndt/15.suppl_8.28
De Vita S, et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum 2012; 64: 843–853. doi: 10.1002/art.34331
Fayed A, et al. Incidence and characteristics of de novo renal cryoglobulinemia after direct-acting antivirals treatment in an Egyptian hepatitis C cohort. Nephron 2018; 140: 275–281. doi: 10.1159/000493807
Levine JW, et al. Persistent cryoglobulinemic vasculitis following successful treatment of hepatitis C virus. J Rheumatol 2005; 32:1164–1167. PMID: 15940780; https://www.jrheum.org/content/jrheum/32/6/1164.full.pdf